Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(CSE:DMED)

0.0300 -0.0050 (-14.29%)
Streaming Delayed Price Updated: 9:51 AM EDT, Jul 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about DMED

< Previous 1 2 Next >
DiagnaMed Launches Ontario Hydrogen Exploration Campaign in Conjunction with QIMC and INRS; Strengthens Board
Toronto, Ontario--(Newsfile Corp. - July 3, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) ("DiagnaMed" or the "Company"), is pleased to... 
Via Newsfile
DiagnaMed Advances Ontario Natural Hydrogen & Helium Program with Strategic Geological Targeting in Timiskaming Graben
Toronto, Ontario--(Newsfile Corp. - June 17, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed" or the "Company"), a Canadian technology... 
Via Newsfile
DiagnaMed Appoints John Karagiannidis as President & CEO; Fabio Chianelli Transitions to Director Role Strengthening Strategic Partnership with QIMC to Accelerate Natural Hydrogen Development in Ontario
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Expands Clean Hydrogen Energy Extraction Capabilities to Demonstrate Proof of Concept of Proprietary Technology
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Acquires Strategic Ontario Claims Adjacent to QIMC in Premier Temiscamingue Hydrogen District
From DiagnaMed Holdings Corp.
Via GlobeNewswire
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
From Revive Therapeutics Ltd.
Via GlobeNewswire
DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed", "DMED", or the "Company"), a leading... 
Via Newsfile
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
From Revive Therapeutics Ltd.
Via GlobeNewswire
DiagnaMed Announces LIFE Offering of up to $510,000
Toronto, Ontario--(Newsfile Corp. - February 27, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed" or the "Company"), a leading... 
Via Newsfile
Topics Artificial Intelligence
DiagnaMed To Support Quebec's Hydrogen Ambitions Through its Collaboration with QIMC
Toronto, Ontario--(Newsfile Corp. - February 27, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed", "DMED", or the "Company"),... 
Via Newsfile
Topics Emissions
DiagnaMed Advances Hydrogen Energy Technology Innovation
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed and TerraVent Announce Strategic Collaboration for Next-Generation Clean Hydrogen Production
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Announces Resignation of Director and Grant of Stock Options
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed and QIMC to Advance Hydrogen Production Technology at the Ville Marie Clean Natural Renewable Hydrogen Project
A Strategic collaboration to Accelerate Clean Natural Hydrogen Innovation 
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Partners with Texas Tech University to Pioneer Hydrogen Innovation
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed and EIREX Collaborate to Develop and Commercialize Novel Modular Technology Producing Hydrogen from Water
Advancing hydrogen for medical and industrial uses 
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Announces Stock Option Grants and Shares for Debt Settlement
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Files U.S. Patent Application for Novel Methods of Producing Molecular Hydrogen
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Advancing the Medical Potential of Hydrogen
Focusing on novel molecular hydrogen therapies for brain health 
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Expands with Drug and Clinical Research AI Platform
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Announces LIFE Offering of up to $650,000
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed’s BRAIN AGE® Brain Health AI Platform Targeting Multi-Billion Digital Brain Health Market
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed’s BRAIN AGE® Brain Health AI Platform Accomplishes Clinical Validation Milestone with Peer-Reviewed Paper
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Announces Canadian Launch of BRAIN AGE® Brain Health AI
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Adds New Launch Site of CERVAI™ Brain Health AI
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Announces BRAIN AGE® Trademark Registration Approved by CIPO
BRAIN AGE® solution is part of the CERVAI™ Brain Health AI Platform 
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Strengthening Intellectual Property Support for CERVAI™ Brain Health AI Solution
Potential $150,000 in non-dilutive funding support through IPON and IP Assist Programs 
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Accelerates Commercialization Initiatives of CERVAI™ Brain Health AI Solution
From DiagnaMed Holdings Corp.
Via GlobeNewswire
DiagnaMed Announces Test Launch of CERVAI™ Brain Health in University Brain Health Center
From DiagnaMed Holdings Corp.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.